EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor/tezacaftor/ivacaftor

Roderick Gavey, James Nolan, Vanessa Moore, David Reid, James Brown

Journal of Cystic Fibrosis · 2024-09 · 23 (5) · 1024-1026

DOI: 10.1016/j.jcf.2024.05.008 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Cystic Fibrosis, 2024-09. Verfasst von Roderick Gavey und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Sleep Medicine, Cairns and Hinterland Hospital and Health Service, Queensland, Australia; Faculty of Medicine, The Univers…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Indoles, Benzodioxoles, Aminophenols. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Elexacaftor/tezacaftor/ivacaftor (ETI) is a CFTR modulator therapy that has dramatically improved the health outcomes for many people with cystic fibrosis (pwCF). There is increasing interest in the role of CFTR modulators in the prevention and treatment of respiratory infections in pwCF. A male patient with F508del homozygous cystic fibrosis developed cavitary Mycobacteroides abscessus subspecies bolletii & massiliense respiratory infection. Antimycobacterial treatment was not given as, in discussion with the patient's family, it was deemed unlikely that the intensive regimen would be tolerated by the patient on account of his autism spectrum disorder. Following initiation of ETI, there was a rapid clinical and radiological improvement in this patient's cavitary lung disease. This case adds to the evidence base that suggests CFTR modulators, particularly ETI, may restore innate immune function leading to improved outcomes for pulmonary infection in pwCF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisIndolesBenzodioxolesAminophenolsQuinolonesMycobacterium Infections, NontuberculousPyridinesHumansMalePyrazolesDrug CombinationsMycobacterium abscessusPyrrolesRespiratory Tract InfectionsCystic Fibrosis Transmembrane Conductance RegulatorAdultPyrrolidines

Stichwörter der Autor:innen

Cystic fibrosisElexacaftor/tezacaftor/ivacaftorMycobacterioides abscessusNontuberculous mycobacterium

Substanzen

IndolesBenzodioxolesAminophenolsQuinolonesPyridinesPyrazolesDrug CombinationsPyrroleselexacaftorCystic Fibrosis Transmembrane Conductance Regulator

Autor:innen und Institutionen

  • Department of Thoracic and Sleep Medicine, Cairns and Hinterland Hospital and Health Service, Queensland, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Electronic address…
  • Adult Cystic Fibrosis Centre, Department of Thoracic Medicine, The Prince Charles Hospital, Queensland, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
  • Adult Cystic Fibrosis Centre, Department of Thoracic Medicine, The Prince Charles Hospital, Queensland, Australia.
  • Department of Thoracic and Sleep Medicine, Cairns and Hinterland Hospital and Health Service, Queensland, Australia.

Zitieren

APA

Gavey, R., Nolan, J., Moore, V., Reid, D., & Brown, J. (2024). Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis, 23(5), 1024-1026. https://doi.org/10.1016/j.jcf.2024.05.008

Vancouver

Gavey R, Nolan J, Moore V, Reid D, Brown J. Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis. 2024;23(5):1024-1026. doi:10.1016/j.jcf.2024.05.008

BibTeX
@article{Gavey2024,
  author = {Gavey, Roderick and Nolan, James and Moore, Vanessa and Reid, David and Brown, James},
  title = {Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor/tezacaftor/ivacaftor},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  volume = {23},
  number = {5},
  pages = {1024--1026},
  doi = {10.1016/j.jcf.2024.05.008}
}
Kostenlos starten →